ArticleReproductive medicine and biology2021
A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis.
Article in Reproductive medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Efficacy and safety of hormone therapies for treating adenomyosis-associated pelvic pain: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2025Pooled it
- A systematic review and Bayesian analysis of the adverse effects of dienogest.BMC pharmacology & toxicology · 2024Pooled it
- Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review.Reproduction & fertility · 2026Review
- Intravaginal progesterone as a fertility-sparing treatment for symptomatic adenomyosis: preliminary results from a monocentric study.Archives of gynecology and obstetrics · 2026Observational
- Clinical Efficacy of Dienogest for Symptomatic Adenomyosis.Journal of clinical medicine · 2026Article
- Uterine transverse diameter and risk of LNG-IUS malposition in adenomyosis patients: a threshold effect analysis from a retrospective cohort study.BMC women's health · 2025Article
- Clinical evaluation and management of endometriosis: 2024 guideline for Korean patients from the Korean Society of Endometriosis.Obstetrics & gynecology science · 2025Article
- Risk factors and countermeasures for abnormal uterine bleeding during dienogest therapy for adenomyosis: a review.Frontiers in reproductive health · 2025Review
- The Role of Different Medical Therapies in the Management of Adenomyosis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Review
- Individualized conservative therapeutic strategies for adenomyosis with the aim of preserving fertility.Frontiers in medicine · 2023Review
- A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis.Reproductive medicine and biology · 2021Article
- Comparison of efficacy between levonorgestrel intrauterine system and dienogest in adenomyosis: a randomized clinical trial.Therapeutic advances in reproductive healthArticle
- The Asian Society of Endometriosis and Adenomyosis guidelines for managing adenomyosis.Reproductive medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of two progestins, levonorgestrel intrauterine system (LNG-IUS) and dienogest (DNG), for adenomyosis.
methodsThis study enrolled 157 women with adenomyosis, randomized to either LNG-IUS (
resultsLNG-IUS and DNG comparably reduced pain scores in patients with adenomyosis. With regard to pain control, DNG offered greater efficacy than LNG-IUS in 3 months of treatment. In all types of adenomyosis, the days of bleeding after 12 months with DNG were significantly decreased compared to those with LNG-IUS. The decrease of whole uterine body was transient in any subtypes. A comparable decrease in BMD due to age-related changes in both groups was observed.
conclusionsLNG-IUS and DNG could be useful for long-term management of adenomyosis. In terms of durations of uterine bleeding, DNG was superior to LNG-IUS for 6 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.